NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

What's the purpose of the trial?

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Trial status

Accepting patients

Phase
Phase 2
Enrollment
125
Last Updated
2 months ago
Am I Eligible

Participating Centers

There are 24 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Alectinib is a tyrosine kinase inhibitor for ALK (anaplastic lymphoma kinase) gene mutations.
  • Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.
  • Entrectinib is a first generation TRK inhibitor that is used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.
  • GDC-6036

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

ALK Cohort

Accepting patients

ROS 1 Cohort

Accepting patients

NTRK Cohort

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(831) 888-0898

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.